將C57鼠每日由腹腔注射脂多醣體(lipopolysaccharide，LPS，120μg/25g C57鼠)，連續注射14日，以建立由LPS所誘發C57鼠腎病變動物模式。經脂多醣體誘發C57鼠腎病變後，然後以3-胺基苯甲醯胺(3-aminobenzamide，3-AB，2.5 mg/25g C57鼠)口服給藥，連續16日後，發現腎病變鼠的尿蛋白，血清中肌酸酐、亞硝酸鹽/硝酸鹽(Nitrite / Nitrate)含量漸漸降低。C57鼠腎病變的腎清除功能亦恢復了近百分之九十。由脂多醣體誘發C57鼠腎病變的經3-胺基苯甲醯胺口服治療16日後，該C57鼠血清中腫瘤壞死因子(Tumor Necrosis Factor-α，TNF-α)、介白素(Interleukin-1β，IL-1β)及前列腺素E2 (Prostaglandinas E2，PGE2)含量也明顯降低。
同時，病理檢查也顯示以口服3-胺基苯甲醯胺治療後的該C57鼠腎病變之腎組織，其髓過氧化物活性(Myeloperoxidase，MPO)也下降，一氧化氮合成(nitric oxide synthase，NOS)及環氧(Cyclooxygenase-2， COX-2)的表現也顯著降低。腎病變C57鼠的腎組織顯著減緩了腎病變期中腎絲球變大、膈細胞的增生。
總結，口服3-胺基苯甲醯胺治療可明顯改善由脂多醣體所誘發C57鼠腎組織病變及腎功能衰退，其機轉可能是經由降低腎病組織一氧化氮合成及環氧(COX-2)的表現並降低發炎性細胞激素(cytokine)的生成而達成。

To study the nephritis in mouse model, each of the C57 mouse was first injected with 120 μg lipopolysaccharide (LPS) intraperitoneally for 14 days. The abnormally higher urine protein content and serum creatinine level typical of nephritic manifestations were detected and maintained for at least 16 days after termination of LPS treatment in all LPS-induced nephritic C57 mice. These high levels of urine protein, nitrite/nitrate, serum creatinine, serum PGE2, serum IL-1β, and TNF-α of LPS-induced nephritic syndrome in C57 mice were gradually decreased following oral treatment with 3-aminobenzamide (3-AB, 2.5 mg/mouse) for 16 days. Concurrently, activities of myeloperoxidase(MPO), nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) from extracts of LPS-induced nephritic kidneys were also decreased based on the MPO and SDS-PAGE evaluation, as well as 90% recovery of kidney’s clearance function. Considering all the experimental evidences found in this study, the lessening effect of antioxidant 3-AB on the severity of LPS-induced nephritic in C57 mice, was most likely coming from its ability to reduce the expression of NOS and COX-2.

1.Anderson G.D, Hauser SD, McGarity KL, Bremer ME., Isakson PC, Gregory SA： Selective inhibition of cyclooxygenase(COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97:2672-2679, 1996.
2.Badr KF：Sepsis-associates renal vasoconstriction:potential targets for future therapy. Am J Kid Dis. 20:207-213, 1992.
3.Baylis C, Harton P, Engels K：Endothelial derived relaxing factor (EDRF) controls renal hemodynamics in the normal rat kidney. JASN 1:875-881, 1990.
4.Border WA, Noble NA, Yamamoto JR, Harper Y, Yamaguchi Y, Pierschbacher MD, Ruoslahti E：Natural inhibitor of transforming growth factor-B protects against scarring in experimental kidney disease. Nature Lond. 360:361-364, 1992.
5.Bremer V, Tojo A, Kimura K, Hirata Y, Goto A, Nagamatsu T, Suzuki Y, Omata M：Role of nitic oxide in rat nephrotoxic nephritis: comparison between inducible and constitutive nitric oxide synthase. J Am Soc Nephrol 8:1712-1721, 1997.
6.Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijon-Banos J, Kvien TK, Van MH, Warner T and Zeidler H：Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 38:779-788, 1999.
7.Bustos M ,Coffman TM, Saadi S, Platt JL：Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J Clin Invest 100:1150-1158, 1997.
8.Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, and Williamson B：An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. 72:3666-3670, 1975.
9.Casimir CM and Teahan CG：The respiratory burst of neutrophils and its deficiency In: Hellewell PG, Williams TJ (Eds.), Immunopharmacology of Neutrophils. Academic Press, San Diego, pp. 27-54, 1994.
10.Cavallo T, Granholm NA：Bacterial lipopolysaccharide transforms mesangial into proliferative lupus nephritis without interfering with processing of pathogenic immune complexes in NZB/W mice. Am J Pathol 137:971-978, 1990.
11.Chen YC, Yang LL and Lee TJ：Oroxylin A Inhibition of Lipopolysaccharide-Induced iNOS and COX-2 Gene Expression via Suppression of Nuclear Factor-κB Activation. Biochemical Pharmacology 59:1445-1457, 2000.
12.Christoph T, Joanne B, Fiona PM and John RV：Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-683, 1997.
13.Comibra T, Wiggins R, Noh JW, Merritt S, Phan SH：Transforming growth factor-B production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol. 138:223-234, 1991.
14.Cook HT, Sullivan R：Glomerular nitrite synthesis in situ immune complex glomerulonephritis in the rat. Am J Pathol 139:1047-1052, 1991.
15.Cortran RS, Kumar V, Robbins SL：Robbins Pathologic Basis of Disease, 5th Ed, W. B. Saunders , Philadelphia, pp71-72, 1994.
16.Csaba S, Basilia Z, Michael O and Andrew LS：DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 93: 1753-1758, 1995.
17.Cumming AD, Diredger AA, MacDonald JW, Lindsay RM, Solez K, Linton AL：Vasoactive .hormones in the renal response to systemic sepsis. Am J Kid Dis. 11:23-32, 1988
18.Cuzzocrea S, Zingarelli B, Costantino G, Szabo A, Salzman AL, Caputi AP, and Szabo C： Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. British J of Pharmacology 121:1065-1074, 1997.
19.Damas P, Reuter A, Gysen P, Demonty J, Lamy M and Franchimont P：Tumor necrosis factor and interleukin-serum levels during severe sepsis in humans Crit Care Med 17:975-978, 1989.
20.Daniel R, Martin, Andrew JP, Marc RH and Babu JP：Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am J Physiol Regulatory Integrative Comp Physiol 279:R1834-R1840, 2000.
21.Dejana E, Breviario F, Erroi A, Bussolino F, Mussoni L, Gramse M, Pintucci G, Casali B, Dinarello CA, and Van DJ：Modulation of endothelial cell functions by different molecular species of interleukin-1. Blood 69:695-699, 1987.
22.De Mendez, IH. Daniel J, Bignon and Lambre CR：Peroxidase activities in the hamster bronchoalveolar lining fluid: modifications induced by exposure to silica dust. Exp Lug Res. 15:681-694, 1989.
23.Dueymes M, Fournie GJ, Carentz F, Mignon-conte M, Labarre JF, Conte JJ：In vivo modulation of polyclonal activation of lymphocytes by SOAz, a cyclophosphazene derived drug. Prevention of murine glomerulonephritis induced by chronic injections of lipopolysaccharide. Clin Exp Immunol 59:169-176, 1985.
24.Emancipator SN, Gallo GR, Lamm ME：Experimental IgA nephropathy induced by oral immunization. J Exp Med 157:572-581, 1983.
25.Endo S, Inada K, Ceska M, Takakuwa T, Yamada Y , Nakae H, Kasai T, Yamashita H, Yaki K and Yoshida M：Plasma interleukin 8 and polymophonuclear leukocyte elastase concentrations in patients with septic shock. J Infect 45:136-142,1995.
26.Feuerstein G and Stren AL：Platelet-activating factor and shock. Prog Biochem Pharmacol 22:181-190,1988.
27.Finkel T：Oxygen radicals and signaling. Curr Opin Cell Biol 10:248-253, 1998.
28.Fink MP：Phospholipases A2:potential mediators of systemic inflammatory response syndrome and the multiple organ dyndrome. Crit Care Med 21:957-959, 1993.
29.Fournie GJ, Mignon-Conte MA, Lule J, Gayral-Ta Minh M, Haas S, Bauriand R, Conte JJ：Immune complex glomerulonephritis in mice infected with Escherichia coli. Clin Exp Immunol 42:77-85, 1980.
30.Furchgott RF and Zawadzki JV：The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376, 1980.
31.Gksel Š, Nermina J, Osman T, Beste M A, Berrak C Y：Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sciences 74:563-572, 2003.
32.Haberstroh U, Stilo K, Pocock J, Wolf G, Helmchen U, Wenzel U, Zahner G, Stahl RA, Thaiss F：L-arginie suppresses lipopolysaccharide-induced expression of RANTES in golmeruli. J Am Soc Nephrol 9:203-210, 1998.
33.Hisakawa N, Nishiya K, Tahara K, Matsumori A, Hashimoto K：Down regulation by iron of prostaglandin E2 production by human synovial fibroblast. Annal Rheumatic Disease 57:742-746, 1998.
34.Hortelano S, Diaz-Guerra MJ, Gonzalez-Garcia A, Leonardo E, Gamallo C, Bosca L, Martinez-A C：Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide –activated macrophages and prevents nephritis in MRL/Mp-lpr/lpr. J immunol 158:1402-1408, 1997.
35.Ikemoto S, Sugimura K, Yoshida N, Yasumoto R, Wada S, Yamamoto K, and Kishimoto T：Antitumor effects of Scutellariae radix and its components baicalein, baicalin , and wogonin on bladder cancer cell lines. Urology. 55:951-955, 2000.
36.Izui S, Lambert PH, Fournie GJ, Turler H, Miescher PA：Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: Identification of circulating DNA and renal localization of DNA-anti-DNA complexes. J Exp Med 145:1115-1130, 1977.
37.Karkar AM, Rees AJ：Influence of an established acute phase response on the severity of experimental nephritis. Clinc Expp Immunol 98:295-299, 1994.
38.Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA and O’Neill GP：Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol 52:1113-1125, 1996.
39.Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF：NG-methyl-L-arginine inhibits tumor necrosis –induced hypotension: implication for the involvement of nitric oxide. Proc Natl Acad Sci 87:3629-3632, 1990.
40.Kone BC, Baylis C：Biosynthesis and homestatic roles in the normal kidney. Am J Physiol 272:F561-578, 1997..
41.Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, Hanlon C, Dietzschold B：In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA 90:3024-3027, 1993.
42.Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Siebert K, Isakson PC and Stallings WC： Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648, 1996.
43.Laneuville O, Breuer DK, De Witt DL, Hla T, Funck CD, Smith WL：Differential inhibition of human prostaglandin endo-peroxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271:927-934, 1994.
44.Liu S, Adcock IM, Old RW, Barnes PJ, Evans TW：Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible intric oxide synthase mRNA. Biochem Biophys Res Commun 196:1208-1213, 1993.
45.Lowenstein CJ, Alley EW, Raval P, Snowman AM, Synder SH, Russell SW, Murphy WJ：Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccaride. Proc Natl Acad Sci USA 90:9730-9734, 1993.
46.Mayeux PR：Pathobiology of lipopolysaccharide. J of Toxicology and environmental Health 51:415-435, 1997.
47.Millar CG, Thiemermann C：Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition. Br J Pharmacol. 121:1824-1830, 1997.
48.Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, and Stewart DJ：Lack of role of nitric oxide(NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-α.Arterioscler Thromb Vasc Biol 15:52-57, 1995.
49.Moncada S, Palmer RMJ and Higgs EA：Nitric oxide:physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-141, 1991.
50.Muhl H and Pfeilschifter J：Amplification of nitric oxide synthase expression by nitric oxide in interleukin 1 beta-stimulated rat mesangial cells. J Clin Invest 95:1941-1946, 1995.
51.Nathan C and Xie QW：Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725-13728, 1994.
52.Noronha IL, Kurger C, Andrassy K, Ritz E, and Waldherr R：In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 43:682-692, 1993.
53.Okuda S, Languino LR, Ruoslahti E, and Border WA：Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest. 86:453-462, 1990.
54.Prabal KC, Kai Z, Salvatore C, Mike O and Christoph T：Inhibitors of poly (ADP-ribose) synthetase reduce renal ischemia-reperfusion injury in the anesthetized rat in vivo. FASEB 14:641-651, 2000.
55.Rifai A, Small PA, Teague PO, Ayoub EM：Experimental IgA nephropathy. J Exp Med 150:1161-1171, 1979.
56.Raij L and Baylis C：Glomerular actions of nitric oxide. Kidney Int 48:20-32, 1995
57.Raij L and Shultz PJ：Endothelium-derived relaxing factor, nitric oxide: effects on and production by mesangial cells and the glomerulus. J Am Soc Nephrol 3:1435-1441, 1993.
58.Rees DD, Palmer RM, Schulz R, Hodson HF, and Moncada S：Characterization of three inhibition of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 101:746-752, 1990.
59.Reyes AA, Karl IE, Klahr S：Role of arginine in health and disease. Am J Physiol 36:F331-346, 1994.
60.Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, FitzGerald GA：Distinct roles of prostaglandin H synthase 1 and 2 in T-cell development. J Clin Invest. 103:1469-1477, 1999.
61.Salgo MG, Bermudez E, Squadrito G, and Pryor W：Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes. Arch Biochem Biophys 322:500-505, 1995.
62.Salter M, Knowles RG, and Moncada S：Widespread tissue distribution, species distribution and changes in activity of Ca2+-dependent and Ca2+-independent nitric oxide synthase. FEBS Lett. 291:145-149, 1991.
63.Salvatore C, Basilia Z, Giuseppina C, Andrea S, Andrew LS, Achille PC and Csaba S：Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. The Journal of pharmacology 121:1065-1074, 1997.
64.Schafer AI：Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 35:209-219, 1995.
65.Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG：Oxidant injury of cells: DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 77:1312-1320, 1996.
66.Sekiya K and Okuda H：Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res. Commun. 105:1090-1095, 1982.
67.Shen YC, Sung YJ, Chen CF：Magnolol inhibits Mac-l (CD11b/CD18)-dependent neutrophil adhesion: relationship with its antioxidant effect. Eur J Pharmacol 343:79-86, 1998.
68.Shultz PJ, Archer SL, Rosenberg ME：Inducible nitric oxide synthase mRNA and activity in glomerular mesangial cells. Kidney Int 46:683-689, 1994.
69.Smith WL and Marnett LJ：Prostaglandin endoperoxide synthase:Structure and catalysis. Biochem Biophys Acta 1083:1-17, 1991.
70.Szabo C, Zingarelli B, o’Connor M, Salzman AL：DNA strand breakage, activation of poly-ADP ribosyl synthetase, and celluial energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite. Proc natl Acad Sce USA 93:1753-1758, 1996.
71.Takako A, Shin T, Koji N, Seiichi K, Michiaki A, Nausheen JS, Takayuki I, Kei N, Michiaki U, Seiki M and Hiroshi O：Activation of Reg gene, a gene for insulin-producing β-cell regeneration: Poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)action. Proc Natl Acad Sci USA 98:48-53, 2001.
72.Thiemermann C, Bowes J, Myint FP, Vane JR：Inhibitin of the activity of poly (ADP-ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci 94:679-683, 1997.
73.Victoria C：Nitric oxide and glomerulonephritis. Sem in Nep 19:277-287, 1999.
74.Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C：Mechanisms of suppression of macrophage nitric oxide relase by transforming growth factor beta. J Exp Med 178:605-613, 1993.
75.Wang Q, Jacobs J, DeLeo J, Kruszna H, Kruszyna R, Smith R, Wilcox D：Nitric oxide hemoglobin in mice and rats in endotoxic shock. Life Sciences 49:PL55-60, 1991.
76.Watson J, Riblet R：Genetic control of responses to bacterial lipopolysaccharides in mice: Evidence for a single gene that influences mitogenic and immunogenic responses to lipopolysaccharides. J Exp Med 140:1147-1161, 1974.
77.Weiss SJ：Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989.
78.Wu CC, Hong HJ, Chou TC, Ding YA, Yen MH：Evidence for inducible nitric oxide synthase in spontaneously hypertensive rats. Biochem Biophys Res Commun 228:459-466, 1996.
79.Yu SM, Wu JF, Lin TL, Kuo SC：Inhibition of nitric oxide synthase expression by PPM-18, a novel anti-inflammatory agent, in vitro and in vivo. Biochem J 328:363-369, 1997.
80.Zhang J, Dawson VL, Dawson TM, Snyder SH：Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263:687-689, 1994.